Cube Labs S.p.a. · MIL:CUBE
Cube Labs — Peili Vision Oy — Seed Pitch Deck (2026)
14 slides from Cube Labs's pitch deck, Apr 16, 2026
Slide 1: EFSim: ADHD Diagnosis Redesigned
EFSim ADHD Diagnosis Redesigned! Faster. Objective. Scalable. Peili Vision Oy / mikko.kontio@peilivision.fi / +358 40 777 2241
Slide 2: Peili Vision in a Nutshell
Peili Vision in a Nutshell The Company - Peili Vision Oy ● Founded in Finland in 2015. Active in the UK since 2023. EIC Accelerator Grant 2022. ● Our product EFSim (Executive Function Simulation) specializes in detecting ADHD and more precisely executive function deficits in school and healthcare set
Slide 3: No child should have to wait for help.
No child should have to wait for help. 3
Slide 4: ADHD Diagnosis - Slow and expensive process
ADHD Diagnosis - Slow and expensive process! What is the real price for waiting? For the children and parents? For society? Children DIAGNOSIS with challenges DETAILED AND WAITING LINE ASSESSMENT TREATMENT Up to 8 years in UK! 2250€ per children SUPPORT IN SCHOOLS Time 4
Slide 5: The Solution - EFSim evaluation
The Solution - EFSim evaluation Children DETAILED ASSESSMENT with challenges E DIAGNOSIS AND TREATMENT F 2250 € savings S per children. i m SUPPORT IN SCHOOLS 250 m€ annual savings in UK! Time Remove waiting lines! 5
Slide 6: How EFSim Works
How EFSim Works ● Simulates home environment where child performs common everyday tasks. ● Age: for 8 - 16 years, up to 20 in development. ● WEB based scalable product. ● World leading, evidence based product, publications ● Solution can be used for ADHD and later with Autism and Alzheimer's/dementi
Slide 7: Future Market Potential
Future Market Potential ADHD - NOW AUTISM - 2028 ALZHEIMER - 2030 Total ADHD Market size is Total Autism Market size is Total Alzheimer Market 25B$ and growing 6,2% 7.4B$ and growing 8.5% size is 5.8B$ and growing annually. annually. 19.2% annually. The market potential is calculated using medicatio
Slide 8: FIRST: ADHD Market
FIRST: ADHD Market ● 15-30% of children have executive function challenges and need evaluation. TAM (Global) ● 5-7% of children have ADHD. 22.5 B€ ● Early detection and early intervention are SAM the key factors to overcome the challenge of (EU & UK) waiting lines! 362M€ ● Start from UK & Finland. S
Slide 9: GTM: From Classrooms to Clinics to Home
GTM: From Classrooms to Clinics to Home Phase 1: UK Schools (Ongoing scaling) Phase 3: B2C USA Phase 2: Healthcare (The (The Scale) Target: Assistant Headmasters / Growth Goal) SENCOs (UK). Fueled by SEND Target: Parents who are worried of reform that focuses on executive Target: NHS (UK) Single Poi
Slide 10: Market position
Market position EFSim is used in the beginning of the care pathway for screening enabling early detection and intervention. ➔ Large volumes & scalable solution! ➔ MDR CE IIa certified Main competitors are positioned to support diagnosis only. ➔ Specialized health care & small volumes. ➔ Lacking MDR C
Slide 11: The Roadmap
The Roadmap Past achievements 2026 2027 2028 ● Technology ready and ● UK School market ● R&D focus differential ● R&D focus on B2C validated. CE MDR IIa, from 10 to 200 diagnosis for Autism & model and UKCA & SFDA customers. ADHD & Learning Neurodegenerative approved. Disabilities & Anxiety & diseas
Slide 12: Team Challenging the Traditional Methods
Team Challenging the Traditional Methods Mikko Kontio, M.Sc Timo Nivala Advisors Co-founder & CEO CTO Believing in agile and resilient Architecting EFSim's technical Prof. Juha Salmitaival leadership for a bigger impact infrastructure Professor of Cognitive Psychology & Cognitive Neuroscience, Unive
Slide 13: Clinical Evidence
Clinical Evidence Successful Clinical Trial ● N. 128, 64 TD & 64 ADHD ● EFSim reliably distinguishes between children with ADHD and typically developed (TD) children (AUC 0.822). ● Children in the intended age group prefer EFSim over CPT-3 and regard it fun to use. ➔ EFSim is easy and safe to use! ➔
Slide 14: OUR MISSION!
OUR MISSION! Every child deserves support. We are building the most loved test of neurodiversity and enable early detection and early intervention. Join us on the mission! Peili Vision Oy / mikko.kontio@peilivision.fi / +358 40 777 2241 14